Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Die Brustkrebsbehandlung ist beendet, aber der Schlaf ist nicht zurückgekehrt: Smartphone-Apps werden an 747 Frauen getestet
Ein Keuchen zu hören reicht nicht aus: Warum eine neue Studie Smartphone-Videos bei Notrufen testet
Was ein Ausatmen verraten kann: Neuer Test wird an 1.000 Patienten mit Verdacht auf Magen- und Darmkrebs getestet
Vor den ersten Gedächtnisproblemen: Roche testet Medikament bei Menschen mit Alzheimer-Biomarkern
A Diaper Photo Could Help Spot Liver Disease in Babies: UK Tests AI
Tumor bleibt nach Behandlung: Neue Kombination wird an 1.000 Patienten mit aggressivem Brustkrebs getestet
HIV-Behandlung ohne tägliche Pillen: Gilead testet neues lang wirkendes Schema in zwei Phase-3-Studien

Bevorstehende klinische Studien

Clinical Research Jobs

More jobs

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

Abonnieren